Johnson & Johnson 10-Q Summary: Fiscal Q2 2008
Business Context and Reporting Period
This filing covers the quarterly period ended June 29, 2008, and the fiscal six months ended on the same date. Johnson & Johnson operates through three primary segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. The company reported strong international growth driven by currency fluctuations, while facing operational headwinds in the Pharmaceutical segment due to patent expirations and generic competition.
Key Financial Metrics
| Metric (Fiscal Six Months Ended June 29, 2008) | Value (in Millions) | YoY Change |
|---|---|---|
| Sales to Customers | $32,644 | +8.2% |
| Net Earnings | $6,925 | +22.5% |
| Diluted EPS | $2.43 | +26.4% |
| Gross Margin | 71.3% | +0.3 pts |
| Operating Cash Flow | $6,078 | -9.7% |
| Cash & Cash Equivalents | $12,646 | +62.8% |
| Total Debt (Short + Long Term) | $13,926 | +113.5% |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 8.2% for the six months, driven by a 15.0% increase in international sales (11.6% currency impact) and a 2.4% increase in U.S. sales. The Consumer segment led growth with a 14.7% increase, while Pharmaceuticals grew only 3.2% due to operational declines offset by currency.
- Profitability: Net earnings rose significantly to $6.9 billion, aided by a lower effective tax rate (24.1% vs. 26.4%) and a substantial reduction in In-Process Research & Development (IPR&D) charges ($40 million in 2008 vs. $807 million in 2007).
- Balance Sheet: Total debt increased to $13.9 billion from $6.5 billion a year ago, primarily to fund a $3.6 billion stock repurchase program. Cash and cash equivalents grew to $12.6 billion.
- Segment Performance: The Medical Devices & Diagnostics segment saw operating profit surge 56.5% year-over-year, largely due to the absence of the $807 million IPR&D charge recorded in the prior year.
Guidance, Outlook, and Risks
- Patent Expirations: The company faces significant revenue erosion from the loss of market exclusivity for Risperdal (oral) in the U.S. (expired June 29, 2008) and internationally. Topamax patent expiration in the U.S. is expected in September 2008, though pediatric exclusivity extends protection to March 2009.
- Legal Proceedings: The company is involved in extensive litigation, including product liability cases for Risperdal, Ortho Evra, and Duragesic. It is also defending against patent infringement suits regarding stents (Cordis) and generic challenges to key drugs like Razadyne and Concerta.
- Regulatory & Compliance: The company is cooperating with DOJ and SEC investigations regarding the Foreign Corrupt Practices Act (FCPA) related to improper payments in small-market countries. Additionally, the European Commission initiated an antitrust inquiry into the pharmaceutical sector.
- Dividends: The Board declared a quarterly dividend of $0.460 per share, marking the 46th consecutive year of dividend increases.
Investor Verification Checklist
- Generic Impact: Verify the actual sales decline trajectory for Risperdal and Topamax following patent expirations and the launch of authorized generics.
- Legal Exposure: Monitor the status of the Risperdal state attorney general actions and the outcome of the Risperdal trial scheduled for September 2008.
- FCPA Resolution: Track the progress of the DOJ/SEC investigation into foreign payments and potential settlement terms.
- Debt Utilization: Assess the sustainability of the increased debt load ($13.9B) relative to cash flow generation, given the aggressive stock buyback program.
- ANDA Litigation: Review the status of Abbreviated New Drug Application (ANDA) lawsuits for Razadyne (30-month stay expires August 2008) and Concerta.